6 results about "Hematochezia" patented technology

The application relates to the technical field of traditional Chinese medicine preparation, and particularly discloses a compound traditional Chinese medicine preparation for targeting egg duck and goose egg cytoplasmic disease, which comprises the following components: white head, Coptis chinensis, Huangqi, Phellodendron amurense, wine Danpi, bran-fried peach kernel, Chinese perilla, pomegranate peel, liquorice, honeysuckle, Andrographis, figwort, emblic, ginger, fried atractylodes, fried safflower, Xianhecao, spiny amaranth, and Poria cocos. Through the combination of monarch, minister, assistant and messenger, the core effects of heat-clearing and detoxifying, blood-cooling and dysentery-stopping, and dampness-drying and insect-killing of the medicines are synergistically exerted, the pathogenesis characteristics of the egg cytoplasmic disease are accurately targeted, blood stasis and blood circulation are promoted to eliminate the swelling of the lesion, and the intestinal mucosa damage is repaired to stop bleeding, the symptoms of hematochezia, diarrhea and oviduct inflammation of the egg duck and goose caused by the egg cytoplasmic disease are effectively relieved, the problems of the decreased antibiotic effect, drug residue, bacterial flora disorder and food safety risk are effectively solved, and the compound traditional Chinese medicine preparation has the remarkable progress of drug resistance, safety, no residue, intestinal protection and green environmental protection.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine intestinal administration preparation for treating UC and a preparation method. The traditional Chinese medicine intestinal administration preparation for treating UC comprises the following raw material medicines in parts by weight: 20-50 parts of rhizoma coptidis, 20-50 parts of cortex phellodendri, 20-50 parts of radix sanguisorbae, 20-50 parts of radix paeoniae alba, 20-50 parts of rhizoma bletillae, 10-40 parts of radix sophorae flavescentis and 10-40 parts of liquorice root. The composition is prepared by combining various medicines, has the effects of eliminating dampness and heat, cooling blood, stopping bleeding, astringing sores and promoting tissue regeneration, and the seven medicines are used together, so that the treatment effect is improved, a synergistic effect is achieved, and the composition is good in effect and free of toxic and side effects when being used for clinical treatment of UC for a long time; the preparation has strong heat-clearing and bleeding-stopping effects, can quickly relieve symptoms such as stomachache, tenesmus and hematochezia caused by UC, and effectively promotes intestinal mucosa healing.

The application discloses a traditional Chinese medicine composition for treating ulcerative colitis and a preparation method and application thereof, and relates to a traditional Chinese medicine composition for treating ulcerative colitis, which is composed of the following components in proportion by weight: radix astragali, rhizoma coptidis, radix scrophulariae, bletilla striata, indigo naturalis, rhizoma corydalis and radix glycyrrhizae. The application has the following remarkable advantages: remarkable synergistic effect, the effect of the traditional Chinese medicine composition of the application on improving the weight loss, hematochezia, DAI score and reducing intestinal inflammation of ulcerative colitis mice is remarkably better than that of any single medicine in the important composition, which proves that there is a remarkable synergistic effect among the components; the mucosal barrier protection is better than that of infliximab; the comprehensive curative effect is equivalent, and the compliance is better; and the drug economy has the advantages that the medicinal materials selected by the application are common traditional Chinese medicines, are widely sourced and are low in price, thereby greatly reducing the treatment cost of patients and being suitable for long-term maintenance treatment.

The invention discloses application of a gingko armillaria mellea oral solution in preparation of a medicine for preventing and treating inflammatory bowel diseases. Through a prevention and treatment test of the ginkgo armillaria mellea oral solution on mouse ulcerative colitis, a C57BL / 6 mouse DSS induction method is adopted to construct a model, and the effect of 390mg / kg and 780mg / kg of the ginkgo armillaria mellea oral solution on resisting mouse inflammatory bowel diseases is evaluated. The result shows that the gingko armillaria mellea oral solution can obviously improve the mouse hematochezia condition; the colon length is increased, the colon weight / length ratio is reduced, and colonic mucosa hyperemia is reduced; the weight is increased. Therefore, the gingko armillaria mellea oral solution has the characteristics of high efficiency and low toxicity for preventing and / or treating inflammatory bowel diseases.

The invention belongs to the technical field of biological medicines, and relates to application of exogenous mitochondria in preparation of a medicine for treating colitis, and the exogenous mitochondria is derived from mammary epithelial cells. The exogenous mitochondria derived from mammary epithelial cells is used for treating young individual colitis for the first time, and the symptoms including inhibition of weight loss, improvement of diarrhea and hemafecia, repair of colonic mucosal lesion (such as crypt structure damage and inflammatory cell infiltration) and / or reduction of disease activity index (DAI score) can be remarkably relieved; the problems that in the prior art, mitochondria sources are limited, oral stability is poor, and the curative effect verification of a young model is insufficient are solved, and a new strategy is provided for colitis treatment.

The invention discloses a macrolide compound and application thereof in preparation of a product for treating ulcerative colitis, and relates to the technical field of biological medicines. In the research process of a secondary metabolite of a strain Penicillium brefeldianum GXIMD 02511 sourced from rhizosphere bottom mud in a mangrove forest protection area at the river estuary of Guangxi province, a macrolide compound brefeldin N is obtained through separation, and the macrolide compound brefeldin N has a remarkable treatment effect on DSS-induced ulcerative colitis mice and can be used for preparing a medicine for treating the ulcerative colitis. Clinical symptoms such as weight loss, hemafecia and diarrhea in the acute stage are remarkably relieved, colon shortening is relieved, pathological injuries are improved, and the effect is better than that of 5-ASA. Therefore, the compound is an ideal candidate compound developed into a novel medicine for treating ulcerative colitis.